Legend Biotech Corporation — Form 6-K Summary
Reporting date: October 13, 2026. The filing reports preliminary CARVYKTI sales for the quarter ended September 30, 2026.
Business context and key financial information
Legend Biotech announced that CARVYKTI generated approximately $710 million in net trade sales during the quarter. The sales figure was provided by Janssen under the companies’ collaboration and license agreement.
This is a preliminary product-sales figure, not Legend Biotech’s reported revenue or gross profit. Management had not completed its financial statements for the period, so the amount of revenue or gross profit Legend Biotech will record was not yet determined. The filing provides no other quarterly financial metrics, including profit, cash flow, margins, debt or liquidity.
Comparisons and outlook
The filing does not provide a prior-period comparison or specific financial guidance. It refers to expectations for CARVYKTI net trade sales and resulting gross profit but gives no forecast amounts.
Caveats, risks and unusual items
- Legend Biotech stated that it had not independently verified Janssen’s sales figure.
- The company’s independent accountants had not audited, reviewed or performed procedures on the data and provided no assurance regarding it.
- Actual results may differ from forward-looking expectations due to clinical, regulatory, partner, intellectual-property, competitive, pricing and political risks, among others.
Important facts for investors to verify
- Whether the preliminary $710 million sales figure is confirmed in subsequent company disclosures.
- How much revenue and gross profit Legend Biotech ultimately records from CARVYKTI for the quarter.
- Whether completed quarterly financial statements provide comparable-period results and additional financial metrics.